Comparative Study of Therapeutic Effect of Dibenyline, Finasteride, and Combination Drugs for Symptomatic Benign Prostatic Hyperplasia

In a 1998 study involving 190 men with severe prostatism, the therapeutic effects of dibenyline, finasteride, and their combination for benign prostatic hyperplasia (BPH) were evaluated. After 6 months, all treatments improved the International Prostate Symptom Score (IPSS), with the finasteride and combination groups showing a decrease in prostatic volume by 24.3% and 10.5%, respectively. The dibenyline and combination groups had significant improvements in maximal flow rate (Qmax) at 3 months, and all groups showed improvements at 6 months. Quality of life was satisfactory in 71.9% of the dibenyline group, 70.4% of the finasteride group, and 83.1% of the combination group. Side effects and dropout rates were highest in the dibenyline group. Upon discontinuation of medication, symptom relapse occurred in 92.6% of the dibenyline group, 57.6% of the finasteride group, and 71% of the combination group. The study concluded that medical treatment is effective for symptomatic BPH and that the combination of dibenyline and finasteride provides a weak synergistic effect without additional side effects.